Oncimmune (LON:ONC) Shares Down 6.3%

Oncimmune Holdings plc (LON:ONCGet Free Report)’s stock price traded down 6.3% during trading on Monday . The company traded as low as GBX 22.50 ($0.28) and last traded at GBX 22.50 ($0.28). 41,218 shares traded hands during trading, a decline of 40% from the average session volume of 68,977 shares. The stock had previously closed at GBX 24 ($0.30).

Oncimmune Stock Down 6.3 %

The business’s 50 day moving average is GBX 25.91 and its 200 day moving average is GBX 21.95. The company has a debt-to-equity ratio of 677.62, a quick ratio of 0.63 and a current ratio of 0.46. The stock has a market cap of £16.68 million, a price-to-earnings ratio of -160.71 and a beta of 1.16.

Insider Buying and Selling at Oncimmune

In related news, insider Martin Gouldstone bought 36,023 shares of the firm’s stock in a transaction on Friday, December 8th. The stock was bought at an average price of GBX 27 ($0.34) per share, with a total value of £9,726.21 ($12,283.67). Company insiders own 28.82% of the company’s stock.

About Oncimmune

(Get Free Report)

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.

Further Reading

Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.